Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29280483
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Lien Goggle trad https://translate.google.fr/translate?h ... 2F292804833,4-Diaminopyridine Base Effectively Treats the Weakness of Lambert-Eaton Myasthenia.
Sanders DB1, Juel VC1, Harati Y2, Smith AG3, Peltier AC4, Marburger T5, Lou JS6, Pascuzzi RM7, Richman DP8, Xie T9, Demmel V10, Jacobus LR11, Aleš KL11, Jacobus DP11; DAPPER Study Team.
Muscle Nerve. 2017 Dec 27. doi: 10.1002/mus.26052.
3,4-diaminopyridine has been used to treat Lambert Eaton myasthenia (LEM) for thirty years despite the lack of conclusive evidence of efficacy.
We conducted a randomized double-blind placebo-controlled withdrawal study in LEM patients who had been on stable regimens of 3,4-diaminopyridine base (3,4-DAP) for ≥ 3 months. The primary efficacy endpoint was >30% deterioration in Triple Timed Up-and-Go (3TUG) times during tapered drug withdrawal. The secondary endpoint was self-assessment of LEM-related weakness (W-SAS).
32 participants were randomized to continuous 3,4-DAP or placebo. None of the 14 receiving continuous 3,4-DAP had >30% deterioration in 3TUG time vs 72% of the 18 who tapered to placebo (p<0.0001). W-SAS similarly demonstrated an advantage for continuous treatment over placebo (p<0.0001). Need for rescue and adverse events were more common in the placebo group.
This trial provides significant evidence of efficacy of 3,4-DAP in the maintenance of strength in LEM.